



COMPANY

Website: <https://mamanbiomedical.ca/>

Year Established: 2024

Patents: Filed 3 families with 2025 priority.

Trademarks: Filed 2 Jan 2025.

Stage: Pre-Commercialization, Pre-Revenue

Industry: Life Sciences – Fem Tech

E-mail: latchmi@mamanbiomedical.ca

TEAM

Founders and Management Team:

Founder & CEO - Dr. Latchmi Raghunanan, PhD Materials Science. 5 granted patents, 15 peer-reviewed publications, 4 years leading R&D & IP at an early-stage medical device startup.

Co-founder & CBO - Roopchand Raghunanan, PMP, PgMP. +20 years governance & executive-level leadership. *Superpowers: High in EQ & Diplomacy.*

Board of Advisors:

Medical Director & Reproductive Expert, Clinical & Regulatory Expert, Device Controls Engineer, Biomaterials Translational Scientist, BioFluid Mechanics Scientist.

FINANCIAL INFO

Revenue: Pre-revenue

Monthly Burn: \$40,000

Funding to Date: \$787,000

Nondilutive: \$500,000+

Raising: \$3M in two tranches for a 24-mth runway (\$500k Tranche 1; \$2.5M Tranche 2)

Capital Seeking: \$500k (Tranche 1)

USE OF FUNDS

Tranche 1: complete value-inflexion milestones that would position us for a strong Tranche 2 raise. We'll use funds to leverage 1.5x nondilutive funding, completing **pilot manufacturing and preclinical validation Maman Port**

- 40% Product Development & Regulatory
- 21% Legal/ IP
- 29% Operations
- 10% Business Development

Tranche 2: commercialize Maman Port

COMPANY OVERVIEW

Maman Biomedical is a Canadian medtech company advancing toward commercialization of Maman Port™, a needle-free drug delivery device designed to replace hypodermic injections in routine self-administered therapies.

Problem: Fertility treatment sits within a \$100B global market for routine self-administered drug delivery. But treatment by self-administered injections is hugely invasive and excludes the 20% of the population with severe needle phobia.

Value Proposition Statement: We eliminate the need for painful injections with our *needle-free microneedle platform* delivering precise dosing, better compliance, and an improved patient experience.

Technology: Maman Port™, a single-use Class II microneedle array device that replaces hypodermic injections, enabling painless intradermal delivery without requiring drug reformulation or changes to clinical workflows.

Stage of Development: Commercialization preparation

Current progress: Functional prototypes developed (TRL5); intradermal delivery validated in lab models.

Economic Impact: Commercialization of Maman Port will establish a Canadian-developed needle-free drug delivery platform, supporting domestic manufacturing partnerships and contributing to the growth of Canada's medical device sector through high-value R&D and commercialization jobs.

TRACTION

- \$787k total funding to date, including \$500k+ non-dilutive funding
- 3 patent families filed (US + Canada)
- Accepted into mHUB Chicago MedTech commercialization residency
- Co-development partnerships with Megalabs and Go Vertical ICM
- Recruiting 3–5 Founding Clinical Partner fertility clinics across Canada to participate in early clinical validation and become the first commercial adopters of Maman Port following regulatory clearance.

MARKET

Initial Beachhead: North American fertility market, valued at \$4.5B in 2023.

Longer-term Opportunity: Self-administered injectables market, >\$100B globally

BUSINESS MODEL

Revenue Model: B2B2C - Sales via Clinics and Pharmacies.

Go to Market Strategy: Early market entry will occur through a small group of *Founding Clinical Partner clinics* who will serve as the first commercial users of Maman Port and help validate treatment integration prior to broader distribution through fertility clinic and specialty pharmacy channels.

COMMERCIALIZATION PLAN

- 2026: pilot manufacturing, sterilization & biocompatibility validation, regulatory engagement, recruit/onboard 3–5 Founding Clinical Partner clinics
- 2027: QMS certification, Clinical Validation, Regulatory submission
- 2028: Regulatory clearance & market launch.

PARTNERS

